A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
Starting soon · Phase 1
Conditions studied: Diabetes Mellitus
In brief
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
Key facts
- Study ID
- NCT07538466
- Run by
- Addpharma Inc.
- People needed
- 50
- Starts
- 2026-04-01
- Expected to finish
- 2026-05-01
- Last updated by the study team
- 2026-04-20
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
You may not qualify if…
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Where it is running
- H Plus Yangji Hospita — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.